Growing single digits isn’t going to get stock anywhere. Prasco will shake things up a bit with 2 larger ANDAs. We don’t know when last one will be filed yet. 2 smaller filings awaiting FDA approval now are non-news worthy. It rose on Prasco deal future growth news. I think there’s enough in pipeline and with Kirko driving sales that we can actually get consistent sequential growth. Would like to potentially see Kirko take over as CEO and keep Nasrat as chairman down road.
News 
Market Data 
Discover 
